By Claire Townsend, Ph.D., Investigator, GlaxoSmithKline
By Jean-Marie Geoffroy, Ph.D., Director, Pharmaceutical Development, TAP Pharmaceuticals, Inc.
By Frank von Delft, Principle Investigator, Protein Crystallography Group, Structural Genomics Consortium, University of Oxford
By Dr Jan Hauss, Laboratory Manager, Merck KGaA
By Tim Lloyd, Editor, European Pharmaceutical Review
By Howard Smith, Technical and Commercial Manager, Cambridge Biostability
By Prof. P. A. Barnes, School of Applied Sciences, Prof. E. L. Charsley, Head of the Centre for Thermal Studies and Dr G. M. B. Parkes, Senior Lecturer in Analytical Science, University of Huddersfield
By Walter Kolch, University of Glasgow & Beatson Institute for Cancer Research
By Ina Poser, Project Leader and Frank Buchholz Group Leader, Max Planck Institute of Molecular Cell Biology
By Susann Schenk, Center for Experimental Bioinformatics (CEBI) and Gary J. Schoenhals, Bioinformatics, Department of Biochemistry and Molecular Biology University of Southern Denmark
By Aidas Kriauciunas and William Roell, Department of Integrative Biology, Shaoyou Chu, Karen Cox and Jonathan A. Lee, Department of Lead Generation Biology and Lead Optimization Biology, Ann Goodspeed, Discovery Informatics, Louis Stancato, Cancer Growth and Translational Genetics, Mark Uhlik, Tumor Microenvironment Biology, Lilly Research Laboratory, Eli Lilly and Company
By Dominique Perrin, Alexander Scheer and Timothy N.C. Wells, Serono Pharmaceutical Research Institute
By Collette S. DeChard, Manager Compound Management Group, Fredric J. Solomon, Senior Automation Project Engineer, Robert Donnenberg Lead Application Services, Merck & Co., Inc.
By Carl-Fredrik Mandenius, Linköping University, Sweden, Member of the European Federation for Pharmaceutical Sciences PAT Steering Group